The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma

Journal of Hepatology

Volumn 52, Issue 1, 2010, Pages 63-71

  Aihara, Arihiro ^a   Tanaka, Shinji ^a   Yasen, Mahmut ^a   Matsumura, Satoshi ^a   Mitsunori, Yusuke ^a   Murakata, Ayano ^a   Noguchi, Norio ^a   Kudo, Atsushi ^a   Nakamura, Noriaki ^a   Ito, Koji ^a   Arii, Shigeki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Aurora B kinase; AZD1152; Hepatocellular carcinoma; Molecular targeted agent; Orthotopic model

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; AURORA B KINASE; HISTONE H3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HISTONES; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; PHOSPHORIC ACID ESTERS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71149108902     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.10.013     Document Type: Article

References (42)

1. Farazi P.A., and DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6 (2006) 674-687
2. Ince N., and Wands J.R. The increasing incidence of hepatocellular carcinoma. N Engl J Med 340 (1999) 798-799
3. Arii S., Yamaoka Y., Futagawa S., Inoue K., Kobayashi K., Kojiro M., et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32 (2000) 1224-1229
4. Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med 359 (2008) 2045-2047
5. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
6. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
7. Zhu A.X. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112 (2008) 250-259
8. Tanaka S., Sugimachi K., Maehara S., Harimoto N., Shirabe K., and Wands J.R. Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma. Surgery 131 (2002) S142-S147
9. Tanaka S., Noguchi N., Ochiai T., Kudo A., Nakamura N., Ito K., et al. Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting Milan criteria: rationale for partial hepatectomy as first strategy. J Am Coll Surg 204 (2007) 1-6
10. Tanaka S., Arii S., Yasen M., Mogushi K., Su N.T., Zhao C., et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 95 (2008) 611-619
11. Lee E.C., Frolov A., Li R., Ayala G., and Greenberg N.M. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 66 (2006) 4996-5002
12. Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17 (1998) 3052-3065
13. Li D., Zhu J., Firozi P.F., Abbruzzese J.L., Evans D.B., Cleary K., et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9 (2003) 991-997
14. Smith S.L., Bowers N.L., Betticher D.C., Gautschi O., Ratschiller D., Hoban P.R., et al. Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 93 (2005) 719-729
15. Tanaka T., Kimura M., Matsunaga K., Fukada D., Mori H., and Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 59 (1999) 2041-2044
16. Sorrentino R., Libertini S., Pallante P.L., Troncone G., Palombini L., Bavetsias V., et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90 (2005) 928-935
17. Gautschi O., Heighway J., Mack P.C., Purnell P.R., Lara Jr. P.N., and Gandara D.R. Aurora kinases as anticancer drug targets. Clin Cancer Res 14 (2008) 1639-1648
18. Keen N., and Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4 (2004) 927-936
19. Macarulla T., Ramos F.J., and Tabernero J. Aurora kinase family: a new target for anticancer drug. Recent Patents Anticancer Drug Discov 3 (2008) 114-122
20. Wilkinson R.W., Odedra R., Heaton S.P., Wedge S.R., Keen N.J., Crafter C., et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13 (2007) 3682-3688
21. Yang J., Ikezoe T., Nishioka C., Tasaka T., Taniguchi A., Kuwayama Y., et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 110 (2007) 2034-2040
22. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359 (2008) 1995-2004
23. Tredan O., Galmarini C.M., Patel K., and Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99 (2007) 1441-1454
24. Han C., and Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 280 (2005) 24053-24063
25. Lu Y.S., Kashida Y., Kulp S.K., Wang Y.C., Wang D., Hung J.H., et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46 (2007) 1119-1130
26. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10 (2004) 262-267
27. Soncini C., Carpinelli P., Gianellini L., Fancelli D., Vianello P., Rusconi L., et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 12 (2006) 4080-4089
28. Tanaka S., Pero S.C., Taguchi K., Shimada M., Mori M., Krag D.N., et al. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst 98 (2006) 491-498
29. Tanaka S., Sugimachi K., Yamashita Yi Y., Ohga T., Shirabe K., Shimada M., et al. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 35 (2002) 861-867
30. Raskopf E., Dzienisowicz C., Hilbert T., Rabe C., Leifeld L., Wernert N., et al. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. Hepatology 41 (2005) 1233-1240
31. Gizatullin F., Yao Y., Kung V., Harding M.W., Loda M., and Shapiro G.I. The Aurora kinase inhibitor VX680 induces endoreduplication and apoptosis preferentially in cells compromised p53-dependent postmitotic checkpoint function. Cancer Res 66 (2006) 7668-7677
32. Bressac B., Galvin K.M., Liang T.J., Isselbacher K.J., Wands J.R., and Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 87 (1990) 1973-1977
33. Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., et al. P53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis (Lond.) 14 (1993) 987-992
34. Tanaka S., Toh Y., Adachi E., Matsumata T., Mori R., and Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 53 (1993) 2884-2887
35. Mortlock A.A., Foote K.M., Heron N.M., Jung F.H., Pasquet G., Lohmann J.J., et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 50 (2007) 2213-2224
36. Hirota T., Lipp J.J., Toh B.H., and Peters J.M. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 438 (2005) 1176-1180
37. Maret A., Galy B., Arnaud E., Bayard F., and Prats H. Inhibition of fibroblast growth factor 2 expression by antisense RNA induced a loss of the transformed phenotype in a human hepatoma cell line. Cancer Res 55 (1995) 5075-5079
38. Giet R., Petretti C., and Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link?. Trends Cell Biol 15 (2005) 241-250
39. Hontz A.E., Li S.A., Lingle W.L., Negron V., Bruzek A., Salisbury J.L., et al. Aurora A and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia. Cancer Res 67 (2007) 2957-2963
40. Warner S.L., Bearss D.J., Han H., and Von Hoff D.D. Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2 (2003) 589-595
41. Carmena M., and Earnshaw W.C. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4 (2003) 842-854
42. Yao X., Hu J.F., Daniels M., Yien H., Lu H., Sharan H., et al. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res 9 (2003) 2719-2726